Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Phase 2 Study ◽

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4576 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4576-TPS4576 ◽

Cited By ~ 6

Author(s):

Ashish M. Kamat ◽

Joaquim Bellmunt ◽

Toni K. Choueiri ◽

Kijoeng Nam ◽

Maria De Santis ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

Phase 2 study of pembrolizumab in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer: KEYNOTE-057

European Urology Supplements ◽

10.1016/s1569-9056(18)31634-8 ◽

2018 ◽

Vol 17 (2) ◽

pp. e1145

Author(s):

J. Bellmunt ◽

M. De Santis ◽

J. Boormans ◽

A. Kamat ◽

T. Choueiri ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

The Journal of Urology ◽

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year

MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN

The Journal of Urology ◽

10.1097/01.ju.0000556224.50163.ad ◽

2019 ◽

Vol 201 (Supplement 4) ◽

Author(s):

Girish S. Kulkarini* ◽

Ronald de Wit ◽

Arjun V. Balar ◽

Ashish Kamat ◽

Edward Uchio ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Annals of Oncology ◽

10.1093/annonc/mdw373.76 ◽

2016 ◽

Vol 27 ◽

pp. vi294

Author(s):

R. de Wit ◽

A.M. Kamat ◽

J. Bellmunt ◽

T.K. Choueiri ◽

K. Nam ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study

European Urology Supplements ◽

10.1016/s1569-9056(19)30557-3 ◽

2019 ◽

Vol 18 (1) ◽

pp. e758-e759 ◽

Cited By ~ 1

Author(s):

J.L. Boormans ◽

A.V. Balar ◽

R. De Wit ◽

A. Kamat ◽

E. Uchio ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

European Urology Supplements ◽

10.1016/s1569-9056(19)31328-4 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1833-e1834 ◽

Cited By ~ 1

Author(s):

J.A. Witjes ◽

J. Gschwend ◽

J. Palou ◽

M. Meng ◽

S. Chang ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Randomized Study ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00147-9 ◽

2021 ◽

Author(s):

Arjun V Balar ◽

Ashish M Kamat ◽

Girish S Kulkarni ◽

Edward M Uchio ◽

Joost L Boormans ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Study ◽

Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study

European Urology ◽

10.1016/j.eururo.2021.07.020 ◽

2021 ◽

Author(s):

Arshvin Kesavan ◽

Kesavan Esuvaranathan

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Study ◽

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?

European Urology Open Science ◽

10.1016/j.euros.2021.01.009 ◽

2021 ◽

Vol 26 ◽

pp. 35-43

Author(s):

Michael E. Rezaee ◽

A. Aziz Ould Ismail ◽

Chiamaka L. Okorie ◽

John D. Seigne ◽

Kristine E. Lynch ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Intravesical Therapy ◽

Cancer Outcomes ◽